Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Completed 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 10Urinary Bladder Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1First-line Treatment 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1

Interventions

Oxaliplatin 81S 1 (combination) 55Capecitabine 44apatinib 32Paclitaxel 32Docetaxel 32Irinotecan 27Fluorouracil 22Drug Therapy 21sintilimab 20Cisplatin 20Leucovorin 16Hyperthermic Intraperitoneal Chemotherapy 13XELOX 12Surgical Procedures, Operative 12camrelizumab 10Trastuzumab 10titanium silicide 9pembrolizumab 9Tegafur 9Nivolumab 9Neoadjuvant Therapy 9Laparoscopy 8Gastrectomy 8Ramucirumab 7Folfox protocol 7Chemotherapy, Adjuvant 7toripalimab 6tislelizumab 6Gastroscopy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Stomach Neoplasms × trifluridine tipiracil drug combination × Clear all
NCT05029102 2024-02-12

TAS-102 and Anlotinib in ≥3 Lines mGC

Zhejiang University

Phase 2 Unknown
45 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡